Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CLAM in AML and High-Risk MDS
NCT02044796Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2014
- Primary completion
- Mar 2018
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Jan 2014; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02044796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044796.